BoWangMD

Bo Wang MD. Executive Member, Lung Cancer Research at Sarah Cannon Research Institute. Hematology-Oncology Willamette Valley Cancer Institute. Views are my own.

[BoWangMD @BoWangMD1]

My biggest takeaways for #WCLC25 plenary:
1) Flaura2 confirmed as a go to regimen for most classical EGFRmut NSCLC
2) Ivonesvimab + chemo shows benefit over chemotherapy alone in a western population post TKI (EGFRmut)
3) zidesamtinib for ROS1 promising, needs much more maturity

[BoWangMD @BoWangMD1]

Delighted to run into another Bowdoin polar bear at ASCO 2026!! Hannah Bogardus 2013 and Bo Wang 2011 @BowdoinCollege

[Sarah Cannon Docs @SarahCannonDocs]

Join SCRI at #ASCO26 for Meet the Expert sessions on head and neck cancer, myeloma, leukemia and melanoma. Connect with our investigators at booth 22035. @CesarAPerezMD, @EricLanderMD @LFletcherMD15 @SAStricklandMD @MeredithMcKean @jeffyoriomd @BoWangMD1

[Eric K. Singhi, MD @lungoncdoc]

#ASCO26 is almost here!

Here are just a few of the lung cancer abstracts I’ll be watching closely this year! @ASCO

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

#ASCO26 #ANVIL is in.
➡️Adjuvant nivolumab: negative.

DFS HR 0.97, p=0.78. N=935.
6 years of follow-up. PD-L1≥50%: HR 0.86, p=0.43.

But here's what makes this problematic; put it next to IMpower010 and KEYNOTE-091:
PD-L1≥50%:
• IMpower010 (atezo): HR 0.43 ✓
• KEYNOTE-091 (pembro): HR 0.82 ✗
• ANVIL (nivo): HR 0.86 ✗

PD-L1<1%:
• IMpower010: HR 0.97 ✗
• KEYNOTE-091: HR 0.75 ✓
• ANVIL: HR 0.97 ✗

Three drugs. Three assays. Completely inconsistent results by PD-L1 subgroup. No reproducible biomarker-efficacy relationship across trials.

I do not think this is a nivolumab problem. It's an adjuvant IO problem. We don't understand which patients benefit and after 3 phase IIIs, we still can't reliably select them. ctDNA-guided adjuvant therapy can't come fast enough.
@ASCO @LungCancerRx

[BoWangMD @BoWangMD1]

@RahulBanerjeeMD @fredhutch @UWMedicine So well deserved my friend!!! Congrats 🎉🎊🎈

[BoWangMD @BoWangMD1]

Check out our other new publication on community biomarker testing for NSCLC!

@DavidRSpigel @SarahCannonDocs @WVCancer @jeff_sharman @CAHON_hemonc

https://t.co/hP7SojQYIC

[BoWangMD @BoWangMD1]

We just published findings from the MARIPOSA trial :
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

https://t.co/eUqeHQyZqZ

[Eric K. Singhi, MD @lungoncdoc]

Clear improvement in outcomes with FLAURA2 regimen for EGFRm NSCLC with a TP53 co-mutation. #ELCC26

[BoWangMD @BoWangMD1]

@BalazsHalmosMD Except that’s the celebration you get for placing 17th for most of us. 😆

[Mustafa Özdoğan, MD @ozdogan_md]

The most decisive step on the road to cure in muscle-invasive bladder cancer was met with a standing ovation at #ESMO25 👏👏

A historic moment for uro-oncology.

#BladderCancer #Oncology #Immunotherapy #ADC

@myESMO @OncLive @CParkMD @tugbawitter @Dr_ElvinaA @atakansare2016 @drmukremin @dr_yakupergun @OncoAlert @myESMO @alimurattat @DrYukselUrun

[BoWangMD @BoWangMD1]

Time will tell - the world is anxious to see Harmoni-3 data for global populations.

[Diego A. Díaz-García @diegoadiazg]

🫁 Ivonescimab + chemo vs tislelizumab + chemo in stage IIIB–IV sqNSCLC. #HARMONi-6 @myESMO

Ivonescimab significantly improved PFS: 11.1 vs 6.9 mo (HR 0.60, p<0.0001), showing consistent benefit across PD-L1 subgroups with manageable safety.

Could this dual-target antibody reshape global first-line standards beyond China?

#ESMO25 #CánCare #NSCLC #lcsm

[Jarushka Naidoo @DrJNaidoo]

Ph III PACIFIC2 trial of concurrent chemoRT + durvalumab v pbo in unresectable stage III NSCLC ⁦@JCO_ASCO⁩:

- 328pts
- no diff in PFS (HR 0.85, p=0.247), OS (HR 1.03, p=0.823), ORR, or tox

Negative study, but important data ⁦@OncoAlert⁩ #LCSM https://t.co/uH4Lw09Tfg

[BoWangMD @BoWangMD1]

Learning about lung cancer updates from our colleagues in Phx, AZ

[BoWangMD @BoWangMD1]

@HemOncFellows

[BoWangMD @BoWangMD1]

For 2nd and 3rd year fellows who are thinking about first jobs - remember to apply to many job types! Do academic job talks, interview at community and hybrid hospital employed positions, and physician owned practices, and pharma companies. Take time &amp; learn what’s out there 😀

[BoWangMD @BoWangMD1]

I should amend: #2 meant to write North American (basically USA) - is the biology different ? Hard to tell.

[BoWangMD @BoWangMD1]

My biggest takeaways for #WCLC25 plenary:
1) Flaura2 confirmed as a go to regimen for most classical EGFRmut NSCLC
2) Ivonesvimab + chemo shows benefit over chemotherapy alone in a western population post TKI (EGFRmut)
3) zidesamtinib for ROS1 promising, needs much more maturity

[Giannis Mountzios @g_mountzios]

#WCLC25 : Professor Ahn presenting the much awaited results of Ifinatamab DXd ( iDXd) in pretreated pts with #SCLC :

✅ ORR=48.2% in ITT, 56.3% in 2L, 51% in CFTI<90d
✅ mPFS=4.9m, DoR=5.3m, OS=10.3m
✅ mOS=12m for 2L pts!
✅ ILD in 12.4%

Ph3 IDeate-Lung02 ongoing!

@IASLC @OncBrothers
@OncoAlert @VJOncology

[Dr Amol Akhade @SuyogCancer]

Excellent slide to show standard 1st line treatment for advanced NSCLC with mEGFR . Money 💰 slide @OncoAlert @OncBrothers @medicalwatchBC #WCLC2025

[BoWangMD @BoWangMD1]

#WCLC2025 both taletrectinib and zidesamtinib are promising ROS1 targeting agents. TRUST and ARROS programs are both undergoing development. Taletrectenib already FDA approved and pending phase 3 study in China against crizotinib. I will keep my eyes peeled for both